Not an actual patient.

TOLMAR IS HERE TO PROVIDE TOOLS, RESOURCES, ACCESS, AND SUPPORT FOR YOU, YOUR PATIENTS, AND YOUR PRACTICE

We’re here to help patients with prostate cancer by offering affordable treatment and an extensive selection of support resources

Programs like TOLMARsync^®, Prostate Cancer 360, and IncreMENtal, along with peer-to-peer resources, provide the support your practice and patients may need during ADT

TOLMAR TOTAL SOLUTIONS^® can help with benefit verification; assists with prior authorizations, appeals, and billing and coding inquiries; and includes Tolmar’s Patient Assistance Program (PAP)

ORDERING MADE EASY FOR YOUR PRACTICE

Order ELIGARD^® directly via TOLMARsync, by phone, or online through a majority of urology, oncology, and hospital GPO partners

tolmarsync section

TOLMARsync: EXPECT MORE THAN JUST AN INVENTORY SOLUTION SYSTEM

Optimizing patient management and practice capabilities with an intuitive user interface

TOLMARsync is designed to integrate with your practice’s workflow and ensures patients always have access to treatment

The program also provides solutions to common barriers such as injecting a patient too early, issues in billing reconciliation, and missing GnRH patients. This is done through:

Heightened patient organization

Keep track of your patients, view upcoming injections, optimize inventory levels, prevent early injections, and easily find missing or overdue patients

Rapid benefit verification

Simplified process through the online portal with an average response time of 4 hours

Reporting at every level of your organization

Affording you billing reconciliation, patient navigation support, email notifications, and reminders for overdue patients across practice locations

Providing inventory management assistance, including transferring and recompilation, and email notifications and reminders for overdue patients across practice locations

GIVE YOUR PATIENTS MORE SUPPORT WITH COMPREHENSIVE ADT RESOURCES

Prostate Cancer 360 provides recommendations and tools to help you with ADT management. It is an initiative created by a team of 14 interdisciplinary experts in oncology, urology, primary care, psychology, nutrition, cardiology, exercise physiology, and nursing, and patient representatives

Recognizing that a comprehensive care team is crucial in ADT management, the PC360 initiative works to:

Establish better prevention and management of the adverse effects of ADT through detailed step-by-step roadmaps for healthcare providers and patients, with recommendations for assessment, monitoring, counseling, and referral

Provide patients with detailed information about ADT, including a pre-treatment initiation checklist as well as guidance about what to expect and what will be assessed before and during treatment

Encourage patients with prostate cancer to implement and sustain healthy dietary and exercise practices in addition to taking other steps to enhance quality of life

Experts developed recommendations for ADT management based on existing key guidelines, risk assessment tools, and clinician resources, with specific recommendations across cardiometabolic, bone, sexual, psychological, and lifestyle domains

Know Before You Go:

3 Important Facts About ADT

ADT can control prostate cancer

Male sex hormones, or androgens, fuel the development and progression of prostate cancer

ADT lowers levels of androgens or blocks androgen activity, helping to control prostate cancer

ADT can cause side effects

ADT can cause a range of side effects involving many aspects of health

Not all men experience all of the potential side effects of ADT, and those effects vary in intensity from person to person

ADT side effects can be managed

There are many steps you and  your doctor can take to avoid, minimize, or manage the side effects of ADT

Eating well, being physically  active, and working closely  with your doctor to manage  your health are key

This roadmap will show you how!

PROSTATE CANCER 360 IS CONTINUING TO EXPAND AND PROVIDE INFORMATION ABOUT ADT TREATMENT. LEARN MORE AT PROSTATECANCER360.COM

GET MORE WITH CUSTOMIZED EDUCATIONAL PROGRAMS

Customized peer-to-peer educational programs + product and clinical information

Tolmar is dedicated to meeting the needs of physicians, nurses, residents, and pharmacists in urology and oncology by offering peer-to-peer educational programs.

FIND MORE TOOLS & RESOURCES

Tools & resources are available to help you and your practice with ELIGARD treatment. Explore the library of support available below

MIXING & ADMINISTRATION VIDEO

MIXING & ADMINISTRATION GUIDE

VIRTUAL MIXING & ADMINISTRATION TRAINING SESSIONS

Join ELIGARD’s weekly virtual training sessions for a demonstration of the mixing and administration process. A clinical trainer will be on hand to answer any questions you may have.

for-your-patients

TOLMAR is here to support patients with ELIGARD

From accessing ELIGARD to navigating treatment, Tolmar is here to help patients every step of the way with tools and resources and programs

Find resources below you can share with your patients as they receive treatment with ELIGARD.

PROSTATE CANCER & YOU GUIDE

Provide patients with a comprehensive resource to help them navigate their way through prostate cancer treatment.

UNDERSTANDING ELIGARD

Give this guide to your patients so they know what they can expect with ELIGARD treatment.

PROSTATE CANCER 360 ROADMAP

Share the patient roadmap from PC360 with your patients to help them prepare for ADT and learn how to navigate their diagnosis.

IncreMENtal is the only habit-building program to support patients on ADT and their caregivers as they build a healthier lifestyle. IncreMENtal gives patients small, simple actions that add up over time to help overcome their ADT challenges

Fully online IncreMENtal courses have:

Easy-to-follow food, fitness, and mental health tips

Personal progress tracking to help set and keep goals

Comprehensive information in a simple, digestible format

New weekly information to help change habits step by step

Lessons are completed at the pace of the user, and patients are able to download and print lessons to keep with them as they control their own progress.

IncreMENtal Nurse Brochure

The IncreMENtal Nurse Brochure helps nurses prepare their patients for the IncreMENtal program by providing information covered in the program along with sample lessons, how to get patients to adhere to habit building, and more.

Learn more at IncreMENtalADT.com.

We support patient organizations, national and local professional associations, and patient advocacy groups

American Urological Association 
(AUA)

Society of Urologic Oncology 
(SUO)

Veterans Prostate Cancer Awareness (VPCa)

Large Urology Group Practice Association (LUGPA)

Society of Urologic Nurses and Associates (SUNA)

American Society of Clinical Oncology (ASCO)

ZERO Prostate Cancer

PATIENT ACCESS HELP IS HERE WITH  TOLMAR TOTAL SOLUTIONS

TOLMAR TOTAL SOLUTIONS is a comprehensive suite of reimbursement and patient assistance services dedicated to optimizing patient access to ELIGARD

We offer a full line of patient support services, including benefit verification; assistance with prior authorizations, appeals, and billing and coding inquiries; patient education materials; and our Patient Assistance Program (PAP).

Patients who meet eligibility criteria may be able to receive ELIGARD via our PAP. Download and fill out the patient enrollment form to see if your patients may benefit

COMBAT FINANCIAL TOXICITY WITH ELIGARD

ELIGARD has not had a WAC increase for over 10 years¹

Many patients with cancer face some degree of financial hardship and illness-related money troubles. With ELIGARD, patients can feel confident in the affordability of treatment and that the cost burden is kept as low as possible.

ELIGARD consistently has been one of the lowest wholesale acquisition costs (WACs) in the GnRH market.

*Costs are standardized to represent one month of therapy.

TOLMAR IS COMMITTED TO KEEPING ELIGARD RESPONSIBLY PRICED

sign up for IMPORTANT ELIGARD updates OR REQUEST A REPRESENTATIVE TODAY

ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone.

Reference: 1. Data on file. Tolmar, Inc.; 2025.

Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD^® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Steve-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

Please see full Prescribing Information for ELIGARD.